ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead asset has the potential to compete with Sanofi’s blockbuster Dupixent and why ASLAN decided to delist from the Taiwan Stock Exchange in favour of NASDAQ.
When we look at the immunology field, and you look at certain areas like atopic dermatitis, it's really interesting to see how the launch of new products has brought about a recognition of the unmet need that exists
